Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy

Current Opinion in HIV and AIDS

Volumn 8, Issue 2, 2013, Pages 87-92

  Palmer, Sarah ^a,b,c  

^a Swedish Institute for Communicable Disease Control   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

eradication strategies; HIV 1 monitoring; persistent viremia; plasma HIV 1 RNA

Indexed keywords

5 HYDROXYNAPHTHALENE 1,4 DIONE; ANTIRETROVIRUS AGENT; DISULFIRAM; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; NAPHTHALENE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS RNA; VORINOSTAT;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY DEVICE; LONG TERM CARE; NONHUMAN; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE COPY ASSAY; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 84873478435     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835d80af     Document Type: Review

References (70)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
2. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
3. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4 cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 2012; 109:9523-9528.
4. Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011; 16:535-545.
5. Wyl V, Gianella S, Fischer M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 2011; 6:e27463.
6. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4 lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929-938.
7. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
8. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
9. Sayana S, Javanbakht M, Weinstein M, Khanlou H. Clinical impact and cost of laboratory monitoring need review even in resource-rich setting. J Acquir Immune Defic Syndr 2011; 56:e97-e98.
10. de Boer MG, Wessels E, Claas EC, Kroon FP. Potential influence of moresensitive HIV-1 load detection by the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay on clinical management of HIV-positive pregnant women. J Clin Microbiol 2010; 48:4301-4302.
11. Gueudin M, Plantier JC, Lemee V, et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007; 44:500-505.
12. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
13. Havlir DV, Koelsch KK, Strain MC, et al. Predictors of residual viremia in HIVinfected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191:1164-1168.
14. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
15. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
16. Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004; 35:33-37.
17. Smit E, Bhattacharya S, Osman H, Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 2009; 51:364-365.
18. Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54:724-732.
19. Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012; 60:473-482.
20. Berger A, Scherzed L, Sturmer M, et al. Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation). J Clin Virol 2002; 25 (Suppl 3):S103-S107.
21. Bourlet T, Signori-Schmuck A, Roche L, et al. HIV-1 load comparison using four commercial real-time assays. J Clin Microbiol 2011; 49:292-297.
22. Crump JA, Scott LE, Msuya E, et al. Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods 2009; 162:218-222.
23. Erali M, Hillyard DR. Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol 1999; 37:792-795.
24. Glaubitz J, Sizmann D, Simon CO, et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: Assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011; 50:119-124.
25. Holguin A, Aracil B, Alvarez A, et al. Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5. J Clin Microbiol 2001; 39:1850-1854.
26. Schumacher W, Frick E, Kauselmann M, et al. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38:304-312.
27. Jennings C, Harty B, Granger S, et al. Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. J Clin Microbiol 2012; 50:2737-2747.
28. Lee PK, Kieffer TL, Siliciano RF, Nettles RE. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006; 57:803-805.
29. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: A recurrent events analysis. J Infect Dis 2012; 205:1230-1238.
30. Widdrington J, Payne B, Medhi M, et al. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011; 62:87-92.
31. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. Jama 2001; 286:171-179.
32. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004; 78:968-979.
33. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
34. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-3884.
35. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
36. Dinoso JB, Kim SA, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. PNAS 2009; 106:9403-9408.
37. Gunthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-1327.
38. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328:327-335.
39. Veazey RS, Lackner AA. The gastrointestinal tract and the pathogenesis of AIDS. AIDS 1998; 12:S35-S42.
40. Gandhi, RT, Zheng, L, Bosch, RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 2010; 7:e1000321. doi:10.1371/journal.pmed.1000321.
41. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4 T cell response. J Infect Dis 2011; 203:960-968., 42].
42. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-919.
43. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4 T cells. J Virol 2006; 80:6441-6457.
44. Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 2008; 105:16725-16730.
45. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.
46. Brennan TP, Woods JO, Sedaghat AR, et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4 T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83:8470-8481.
47. Anderson JA, Archin NM, Ince W, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4 T cells. J Virol 2011; 85:5220-5223.
48. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284-1290.
49. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
50. Nunnari G, Argyris E, Fang J, et al. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005; 335:177-184.
51. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002; 76:13077-13082.
52. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-137.
53. Brooks DG, Arlen PA, Gao L, et al. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci USA 2003; 100:12955-12960.
54. Brooks DG, Hamer DH, Arlen PA, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003; 19:413-423.
55. Korin YD, Brooks DG, Brown S, et al. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 2002; 76:8118-8123.
56. Kulkosky J, Culnan DM, Roman J, et al. Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98:3006-3015.
57. Williams SA, Chen LF, Kwon H, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004; 279:42008-42017.
58. Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
59. Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-6789.
60. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005; 366:549-555.
61. Bouchat S, Gatot JS, Kabeya K, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4 T cells from HIV-1-infected HAARTtreated patients. AIDS 2012; 26:1473-1482.
62. Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathogen 2009; 5:e1000554.
63. Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5:e1000495.
64. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119:3473-3486.
65. Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4 T cell model without inducing global T cell activation. J Virol 2011; 85:6060-6064.
66. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
67. Spivak AM, Andrade A, Hoh R, et al. Safety and feasibility of Using disulfiram to enhance HIV transcription among long-term ARV-treated adults: Preliminary results from a pilot study. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012. [Abstract 369]
68. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83:8604-8610.
69. Shen F, Sun B, Kreutz JE, et al. Multiplexed quantification of nucleic acids with large dynamic range using multivolume digital RT-PCR on a rotational SlipChip tested with HIV and hepatitis C viral load. J Am Chem Soc 2011; 133:17705-17712.
70. Anderson EM, Wiegand A, Boltz VF, et al. Single-copy detection of plasma HIV-1 RNA using droplet digital PCR technology. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012.